Nearly two months after a public meeting to discuss the direction of CBD laws, the FDA still has no answers for industry stakeholders.
Across the pond, UK Members of Parliament are targeting companies that haven’t been submitting product samples for cannabis clinical trials. Also, the Cannabis Trades Association publicly disputes the CMC’s new product report. All that and more in this week’s Cannabis Business Weekly Review and Newsletter.
Following a public meeting on May 31st regarding CBD regulations, many were expecting guidance by now but they claim the FDA continues to drag their feet. Lawmakers are now turning up the heat in an attempt to get the FDA to draft some official regulations regarding the sale of CBD-infused food, supplements and cosmetics.
Unless you’ve been living under a rock, you’re likely aware that Colorado was among the first states in the U.S. to legalize recreational cannabis for adults 21 years and older. As a result, there as has been an influx of cannabis dispensaries throughout the Rocky Mountain state. One of the most notable brands in the dispensary circuit is Native Roots, a company that’s home to 20 of Colorado’s top rated medical and recreational dispensaries.
According to a new study commissioned by the London-based Centre for Medicinal Cannabis (CMC), nearly 40% of CBD products sold in the U.K. have a lower cannabidiol content than what’s listed on their labels. Additional tests found that one product even had high enough levels ethanol to legally qualify as an alcoholic beverage.
According to Mike Harlington from The Cannabis Trades Association, “The CMC issued a report a few days ago, and in true CMC form (and UPA and everything else connected with Liebling and Moore) it’s fatally flawed. Anyone who has ever been involved with these people know that they have always gotten entangled with CBD products and medicinal cannabis with an aim to control them.”
Members of Parliament in the U.K. have submitted proposals to ‘name and shame’ companies that haven’t provided cannabis products for use in clinical trials. The newest report released by The House of Commons Health and Social Care Committee entitled ‘Drugs policy: medicinal cannabis’, concluded that one of the main reasons so few cannabis prescriptions have been offered in the U.K. is simply because of fear.
OTHER TRENDING NEWS
CBD, short for Cannabidiol, is an active compound inside cannabis and hemp. Unlike THC, CBD offers many therapeutic benefits without the psychoactive effects. With all the talk surrounding this cannabinoid lately, it can be difficult to separate the real from the fake. Let’s take a look at some of the most common myths and dispel them once and for all.
Vaping CBD has never been so popular and accessible and it’s an ideal solution for people who need immediate relief from their symptoms. When it came to finding the very best CBD Vape Pens on the market in 2019, we were faced with a difficult task, but we were able to come up with a short list of products you should definitely try for yourself.